Cellbion

CellBion is a South Korean biopharmaceutical company and pioneer in the radiopharmaceutical industry, founded in 2010, specializing in the development of cutting-edge radioligand therapies to address unmet medical needs in oncology. The company's flagship program is lutetium (177Lu) pocuvotide satetraxetan, a novel PSMA-targeted radioligand therapeutic designed to treat metastatic castration-resistant prostate cancer (mCRPC) by delivering beta-particle radiation selectively to tumor cells while minimizing damage to healthy tissue. With a GMP facility at Seoul National University Cancer Research Institute and an R&D center at Institut Pasteur Korea, CellBion is advancing a differentiated pipeline in theranostics and combination therapies, working toward conditional approval from South Korea's Ministry of Food and Drug Safety.